SHORT COMMUNICATION

Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis

JIDE TIAN, JING YONG, HOA DANG, & DANIEL L. KAUFMAN

Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA

(Submitted 23 October 2010; revised 11 February 2011; accepted 9 March 2011)

Abstract

Current treatments for rheumatoid arthritis (RA) have long-term side effects such that new treatments are needed that can safely help manage the disease. There is a growing appreciation that GABA receptors (GABA-Rs) on immune cells provide new targets that can be used to modulate immune cell activity. Here, we show for the first time that activation of peripheral GABA-Rs can inhibit the development of disease in the collagen-induced arthritis (CIA) mouse model of RA. Mice that received oral GABA had a reduced incidence of CIA, and those mice that did develop CIA had milder symptoms. T cells from GABA-treated mice displayed reduced proliferative responses to collagen and their APC had a reduced ability to promote the proliferation of collagen-reactive T cells. Thus, GABA downregulated both T-cell autoimmunity and APC activity. Collagen-reactive T cells from GABA-treated mice displayed reduced recall responses in the presence of GABA ex vivo, indicating that GABA consumption did not desensitize these cells to GABA. GABA-treated mice had reduced collagen-reactive IgG2a, but not IgG1 antibodies, consistent with reduced Th1 help. The levels of serum anti-collagen IgG2a antibodies were correlated significantly with the CIA disease scores of individual mice. Our results suggest that activation of peripheral GABA-Rs may provide a new modality to modulate T cell, B cell, and APC activity and help ameliorate RA and other inflammatory diseases.

Keywords: GABA receptor, GABA, rheumatoid arthritis, T cell, APC, anti-collagen antibody, autoimmune

Introduction

GABA receptors (GABA-Rs) are expressed by many neurons in the central nervous system (CNS) as well as other types of cells in the periphery [1]. Our previous studies, and those of others, have showed that GABA-A-R subunits are expressed by mouse T cells and APC, as well as by human T cells and monocytes [2–7]. Treatment with GABA inhibited the development of type 1 diabetes (T1D) in nonobese diabetic mice (NOD) [3] and treatment with a GABA-A-R ligand ameliorated experimental autoimmune encephalitis (EAE) [6]. Accordingly, GABA-A-Rs may be a new class of drug targets for reducing chronic inflammation.

Rheumatoid arthritis (RA) is a chronic inflammatory disorder that affects about 1% of the population [8,9]. T-cell autoimmunity plays a key role in the development and progression of RA. Anti-inflammatory agents and analgesics are useful for treating RA; however, their efficacy and safety remain a concern [10,11]. Therefore, the development of new safe therapeutic reagents that target new pathways and have synergistic beneficial effects with existing treatments will be of great significance in managing RA. While GABA-R modulation can inhibit T1D and EAE, whether it can ameliorate RA is an open question, because RA involves different immune mechanisms and is associated with specific MHC haplotypes.

The collagen-induced arthritis (CIA) model of RA in DBA/1j mice shares many immunological and pathological features with human RA and has been widely used for screening anti-RA drugs (reviewed in [12,13]). We treated collagen-immunized mice with GABA rather than other GABA-A receptor agonists that are in clinical use because the latter were developed to pass through the blood–brain barrier and modulate neuronal GABA-A receptors in the CNS. In contrast, GABA does not pass through the blood–brain barrier.
effectively and is safe for human use, making it an excellent candidate for modulating peripheral immune cell function without CNS side effects.

Materials and methods

CIA induction

All experiments were approved by UCLA’s Animal Research Committee. Male DBA/1j mice (Jackson Laboratories, Bar Harbor, ME, USA) 8–10 weeks of age were immunized with 200 μg bovine collagen II (bCII, Chondrex, Redmond, WA, USA) in 50% complete Freund’s adjuvant (CFA) containing 2 mg/ml Mycobacterium tuberculosis strain H37Ra (Difco, Detroit, MI, USA) intradermally at the base of the tail and were boosted 21 days later with 100 μg of bovine collagen in incomplete Freund’s adjuvant. Their food and water consumption, body weights, as well as joint inflammation were measured longitudinally.

GABA treatment

After the initial immunization, the mice were provided with plain drinking water or water containing 2 mg/ml of GABA (Sigma Aldrich, St. Louis, MO, USA) for the entire 8-week observation period. The water bottles were changed every 7 days with fresh material. Based on our prior observations that the mice drink 4–5 ml of water per day, each experimental mouse consumed approximately 8–10 mg of GABA daily.

Proliferation assays

Groups of DBA/1j mice were immunized and placed on plain water or water + GABA, as above. Ten days after boosting, their splenic mononuclear cells (5 × 10^5/well) were challenged in triplicate with bCII peptide p259-273 (GIAGFKGEQGPKGEP, >95% purity, Biosynthesis) in fetal calf serum (FCS)-free HL-1 medium (in triplicate) for 96 h in the presence or absence of 1 mM of GABA. T-cell proliferation was determined by 3H-thymidine (1 μCi) incorporation, as per [2].

Other groups of DBA/1j mice were immunized with 100 μg of bCII peptide in 50% CFA at the base of the tail and given plain water or water + GABA. Nine days later, their popliteal lymph node and splenic mononuclear cells were prepared independently. Splenic APC and lymph node T cells were purified from control and experimental mice by negative selection using anti-CD3 or anti-CD220, anti-Mac1, and anti-CD11c-conjugated magnetic beads (Miltenyi Biotech, San Diego, CA, USA), respectively. Lymph node T cells (1.5 × 10^5/well) were cultured in triplicate with splenic APCs (5 × 10^5/well) from control or GABA-treated mice and challenged with the bCII peptide for testing T-cell proliferation. Cells cultured in medium alone or stimulated with anti-CD3 (1 μg/ml) were used as negative and positive controls, respectively.

ELISA analysis of collagen-specific antibodies

The levels of serum collagen-specific IgG, IgG1, and IgG2a antibodies in individual control and experimental mice 8 weeks after the final immunization were characterized by ELISA, as described previously [14,15] using 10 μg/ml bCII as antigen for coating the plates.

Results

There was no significant difference in food and water consumption, or body weights between the control and GABA groups over the 8-week observation period (Figure 1). Although 7 out of 8 control mice developed CIA, only 4 out of 7 GABA-treated mice developed CIA symptoms (Figure 2(A)). Similarly, in a second independent study, 11 out of 12 control mice...
developed CIA, but only 6 out of 10 GABA-treated mice displayed CIA symptoms (Figure 2(B), $p = 0.03$, for combined results by Fisher exact analysis). Importantly, the mean clinical scores in GABA-treated mice were significantly reduced compared with that in controls (Figure 2(A) and (B), $p < 0.01$ for each study by Student’s $t$-test). Thus, oral treatment with GABA inhibited the incidence and severity of CIA in mice.

To obtain insights into the mechanism(s) by which GABA treatment inhibited the development of CIA in mice, we tested whether the treatment reduced the development of T-cell responses to collagen. We immunized mice with bCII, provided them with plain water or water + GABA, reboosted them 21 days later, and 10 days later we tested their splenic mononuclear cell responses to the bCII peptide in the presence or absence of GABA (1 mM).

We observed that splenic T cells from GABA-treated mice displayed significantly less proliferative responses to the bCII peptide compared to T cells from control mice (Figure 3, $p < 0.05$ by Student $t$-test). We observed that inclusion of GABA in the media inhibited the proliferation of bCII-reactive T cells from both control and GABA-treated mice (compared to cultures without GABA) to similar extents (Figure 3). Thus, continual GABA consumption did not desensitize activated T cells to GABA.

Because T-cell activation and expansion depends on antigen presentation by APCs, we examined whether oral GABA treatment could also affect APC activity. Nine days after immunization with bCII peptide in CFA, T cells were purified from the popliteal lymph nodes of control or GABA-treated mice and were co-cultured with APCs that were purified from the spleens of control or GABA-treated mice and incubated with a dose range of bCII peptide in vitro to assess their proliferative responses. We found that co-cultures of T cells from control mice and APCs from GABA-treated mice displayed significantly less proliferation than control cultures (Figure 4, $p < 0.05$). Co-cultures of T cells from GABA-treated mice and APCs from control mice displayed even less proliferation, suggesting that GABA mainly affected T cells in vivo. Co-cultures of both T cells and APC from GABA-treated mice displayed the lowest proliferative responses. Together, these data...
indicate that GABA consumption inhibited both the antigen-presenting activity of APC and autoreactive T-cell responses.

Since B cells also contribute to the pathogenesis of RA in mice and humans, we examined whether GABA treatment could modulate the production of autoantibodies against collagen. We found that GABA-treated mice had significantly reduced levels of IgG responses against bCII (Figure 5(A)). In particular, GABA consumption greatly reduced the levels of IgG2a responses to bCII, but had no discernable effect on IgG1 responses to bCII. More importantly, further analysis revealed that the levels of serum IgG2a were correlated significantly with the CIA disease scores of individual control and experimental mice at the end of the 8-week study ($R^2 = 0.8967, p < 0.0001$ by Spearman’s correlation test, Figure 5(B)).

**Discussion**

We show for the first time that activation of peripheral GABA-Rs can reduce disease incidence and severity in an animal model of RA. Spleen cells from GABA-treated mice displayed reduced proliferative responses to the collagen peptide ex vivo. These proliferative responses were reduced by the inclusion of GABA in the media, demonstrating that long-term consumption of GABA did not desensitize cognate T cells to GABA. APCs are known to infiltrate the synovium and play an important role in RA [16,17]. Using co-cultures of purified T cells or APC from collagen peptide-immunized mice that were fed plain water or water + GABA, we showed that GABA treatment downregulated APC function, but that the major effect of treatment was on T cells. We previously reported that GABA treatment inhibits T-cell responses to β-cell antigens in NOD mice, which was associated with the inhibition of T-cell cycling, but not the depletion of immunocompetent cells [3], and Steinman and colleagues have reported that GABA-R activation inhibits MAPK signaling in APC [6]. The ability of GABA treatment to inhibit autoantigen-specific T-cell activation and proliferation and to modulate APC’s activity in vivo may underlie GABA’s ability to inhibit CIA.

B cells also play a major role in the pathogenesis of RA in mice and humans by producing cytokines, presenting antigens and by synthesizing autoantibodies that can target self-tissues or form immune complexes with autoantigens [18–20]. We showed...
that GABA treatment reduced IgG and IgG2a (but not IgG1) responses to bCII. Notably, the levels of serum IgG2a response to bCII were correlated with the CIA disease scores in individual mice. Given that IgG2a antibodies are associated with Th1 help, the significantly reduced anti-collagen IgG2a responses may reflect the effect of GABA on inhibiting Th1 responses in vivo. It will be of interest to further test GABA’s ability to ameliorate inflammatory responses after the establishment of CIA.

Oral GABA was tested in the 1950s–1980s in hundreds of patients for its ability to reduce epileptic seizures and treat cerebrovascular disorders [21–23]. Because GABA has very little ability to cross the blood–brain barrier, several grams of GABA per day were administered to subjects. GABA was found to be safe, but of little clinical benefit and pharmaceutical interests have focused on GABA-R ligands that efficiently cross the blood–brain barrier. Although the inability of GABA to pass through the blood–brain barrier makes it ill-suited for modulating CNS neurons, it makes it an excellent candidate for modulating immune cell function in the periphery without unwanted CNS side effects.

Metabolic studies in humans have observed that after oral consumption of GABA, serum GABA levels peak about 90 min later and decline to baseline about 180 min after consumption [23]. In the present study, GABA was administered through drinking water. This modality may have not elicited a maximal therapeutic effect because the mice drank water intermittently. The development of oral sustained-release formulations of GABA, or safe GABA-R agonists that have a long circulation period and do not pass through the blood–brain barrier, may provide even more efficacious therapies for RA and other inflammatory diseases.

Our findings complement previous findings that GABA can inhibit the spontaneous development of T1D in mice [3], and that a GABA-R agonist can ameliorate EAE [6]. The ability of GABA-R modulation to inhibit the disease process in T1D, EAE, and CIA in mice with different genetic backgrounds seems remarkable for a substance that has little, or no, side effects. Human PBMC populations, including lymphocytes, express functional GABA-Rs [7]. Conceivably, GABA and GABA-R agonists that are unable to pass through the blood–brain barrier may provide a new class of safe therapeutic reagents to modulate T cell and APC activity in ways that help ameliorate RA and other inflammatory diseases.

Declaration of interest: This work was supported, in part, by grants from the National Institute of Diabetes and Digestive and Kidney Diseases to DLK. The authors have a patent on the use of GABA for inflammation. The authors report no other conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References


